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Background: Wnt/β-catenin signaling pathway is essential for the beginning of odontogenesis and may be involved 
in the development and progression of some odontogenic tumors. Thus, the aim of this study was to comparatively 
evaluate the immunohistochemical expression of Wnt/β-catenin signaling pathway proteins in a series of AME and 
CCOT. 
Material and Methods: Immunohistochemical reactions were performed using antibodies against Wnt1, Wnt5a and 
β-catenin in 17 cases of solid AME and 6 cases of CCOT. 
Results: In the AME group, Wnt1 and Wnt5a were identified in the epithelium in most of the cases, and β-catenin 
was mainly identified in the cytoplasm of the tumoral cells. In the CCOT group, Wnt1 and Wnt5a were identified 
in the epithelium and in the ghost cells in almost all the cases, and β-catenin was mainly identified in the cytoplasm 
and in the nuclei of the tumoral cells. 
Conclusions: These results contribute to support the importance of Wnt/β-catenin signaling pathway proteins in 
AME and CCOT tumorigenesis. The abnormal expression of cytoplasmic and/or nuclear β-catenin appears to con-
tribute to the development of both AME and CCOT. In addition, it is possible that Wnt1 and Wnt5a expression in 
ghost cells can contribute to its histogenesis in CCOT.
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Introduction
The Wingless type (Wnt)/β-catenin signaling pathway is 
essential for early odontogenesis activation (1). There is 
also additional evidence of the involvement of this pa-
thway in the development of some odontogenic tumors 
(OT), such as ameloblastoma (AME) (2-4) and calci-
fying cystic odontogenic tumor (CCOT) (4-6). Classi-
cal Wnt/β-catenin signaling pathway, also named the 
canonical pathway, is usually activated by Wnt1 protein 
and inactivated by Wnt5a protein (7). The activation of 
this pathway will stabilize β-catenin, allowing its cyto-
plasmic accumulation and nuclear translocation; in the 
nucleus, β-catenin will participate in the expression of 
genes related to the cell cycle during embryogenesis and 
during the development of some benign and malignant 
tumors (7-9). 
AME and CCOT figure among the four more common 
OT, comprising, respectively, around 30% and 7% of all 
OT in a recent series reported (10). AME is considered a 
locally aggressive benign OT classified in four different 
clinicopathologic variants: solid, unicystic, peripheral 
and desmoplastic (11,12). CCOT is a benign cystic OT 
that is microscopically characterized by an ameloblasto-
ma-like lining epithelium associated with the presence 
of ghost cells (13), and may be associated with an ame-
loblastomatous proliferation in some cases (14).
Herein, the aim of this study was to evaluate the im-
munohistochemical expression of Wnt/β-catenin signa-
ling pathway proteins in AME and CCOT in order to 
highlight the involvement of this pathway in their de-
velopment.
Material and Methods
A total of 17 solid AME and 6 CCOT were selected from 
the files of the Oral Pathology Laboratory, School of 
Dentistry, State University of Rio de Janeiro, Brazil. 
AME affected 10 males and 7 females with ages ran-
ging from 12 to 72 years (mean of 33.9 years). Mandible 
was affected in 14 cases. All cases were microscopica-
lly reviewed and classified according to the histological 
classification of AME described by the World Health 
Organization Histological Classification of Odontogenic 
Tumors (11). Seven cases were classified as plexiform, 
4 cases as follicular, 1 case as acanthomatous and in 5 
cases there was an hybrid pattern including more than 
one histological subtype (Fig. 1A-C).
CCOT affected 6 females with ages ranging from 10 to 
28 years (mean of 17 years). Mandible and maxilla were 
affected in 3 cases each. None of the 6 CCOT were asso-
ciated with any other OT. All cases were microscopica-
lly reviewed and classified according to the histological 
classification of CCOT (15) (Fig. 1D).
For the immunohistochemical reactions, 3-μm tissue 
sections on silane-coated histological slides were incu-
bated with primary antibodies against Wnt1 (polyclonal; 
R&D Systems; 1:100), Wnt5a (clone 442625; R&D 
Systems; 1:50) and β-catenin (clone 17 C 2; Novocas-
tra; 1:100) by using the labeled streptavidin-biotin kit 
(LSAB, Dako) using the immunoperoxidase technique. 
Visualization was acquired with 3,3’diaminobenzidine 
solution (DAB, Dako) and Carazzi’s hematoxylin coun-
terstaining. Positive controls were tumor cells from a 
breast carcinoma (Wnt1), small intestine’s villus (Wn-
Fig. 1. Histological subtypes of AME and CCOT included in this study (hematoxy-
lin and eosin). A, AME plexiform (original magnification, x200); B, AME follicular 
(original magnification, x200); C, AME acanthomatous (original magnification, x200); 
and D, CCOT showing a cystic cavity lined by an ameloblastomatous-like epithelium 
containing a great amount of ghost cells (hematoxylin and eosin, original magnifica-
tion, x100) 
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t5a) and the lining epithelium of a fibrous hyperplasia 
(β-catenin). Internal adjacent tissues of each positive 
control was used as a negative reference of the immu-
nohistochemical reactions. Wnt1 and Wnt5a expression 
was scored as undetectable or detectable, if >5% of tu-
mor cells cytoplasm were positive, and β-catenin expres-
sion was scored as negative, positive on cell membrane, 
positive on cell membrane and cytoplasm, positive on 
cytoplasm, or positive on cytoplasm and nucleus. These 
immunohistochemical expressions were descriptively 
presented.
This study was carried out with the approval of Research 
Ethics Committee (016/2011, May 9, 2011, School of 
Dentistry of Piracicaba, State University of Campinas, 
Brazil) and financial supported by Fundação Carlos 
Chagas Filho de Amparo à Pesquisa do Estado do Rio de 
Janeiro (FAPERJ) and Coordenação de Aperfeiçoamen-
to de Pessoal de Nível Superior (CAPES).
Results
Wnt1 was detectable in the epithelium from 12 cases 
of AME (64.5%) and Wnt5a was detectable in the epi-
thelium from 9 cases of AME (53%). β-catenin showed 
cytoplasmic staining in 12 cases (70.6%), cytoplasmic 
and membranous staining in 2 cases (11.8%) and was 
undetectable in the epithelium from 3 cases of AME 
(17.6%) (Fig. 2). 
Wnt1 and Wnt5a were heterogeneously detectable in the 
lining epithelium from all cases of CCOT (100%). Wnt1 
was also detectable in the ghost cells from 5 CCOT 
(83.3%) and Wnt5a was detectable in the ghost cells 
from all CCOT (100%). β-catenin showed both cyto-
plasmic and nuclei staining in the lining epithelium from 
5 CCOT (83.3%) and was undetectable in the ghost cells 
from all CCOT (100%) (Fig. 3).
Discussion
Wnt family of glycoproteins is one of the major families 
of signaling molecules expressed during the develop-
ment of a multicellular organism and, in adult tissues; 
they may be expressed in homeostatic renewal or in tu-
morigenesis of some benign and malignant neoplasms 
(9,16,17). Traditionally, members of this family are 
divided into two groups according to the potential of 
activating the classical canonical Wnt/β-catenin signa-
ling pathway. The Wnt1 class has a greater potential for 
activating the canonical pathway than the Wnt5a class 
(7,18). Furthermore, it is known that Wnt5a may also act 
as an antagonist of this pathway (18,19).
Wnt1 expression had already been demonstrated in AME 
(16,20,21). It is usually the most common Wnt family 
glycoprotein expressed in AME epithelium, regardless 
of the clinicopathologic subtype (16,20). Nevertheless, 
a study had not identified Wnt1 positivity in follicular 
Fig. 2. Immunoexpression of Wnt/β-catenin signaling pathway proteins in AME epithelium (immunoperoxidase). A, Wnt1 
identified in a plexiform AME (original magnification, x200); B, Wnt5a identified in a plexiform AME (original magnifica-
tion, x400); C, β-catenin identified in a follicular AME (original magnification, x100).
Fig. 3. Immunoexpression of Wnt/β-catenin signaling pathway proteins in CCOT ameloblastoma-like epithelium and ghost 
cells (immunoperoxidase). A, Wnt1 identified in the epithelium and ghost cells of a CCOT (original magnification, x200); B, 
Wnt5a identified in the epithelium and ghost cells of a CCOT (original magnification, x400); C, β-catenin identified only in 
the epithelium of a CCOT (original magnification, x100).
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AME (21). Wnt1 overexpression in the present series 
of AME is justified since Wnt1 is considered the most 
potent canonical signaling pathway activator (7) and, as 
a consequence of this pathway activation, a high cyto-
plasmic expression of β-catenin was also identified (8). 
Even so, the expected nuclear β-catenin translocation 
was not identified in the AME epithelium from our ca-
ses. It is noteworthy that an overexpression of Wnt1 was 
similarly identified in keratocystic odontogenic tumor, a 
common and benign OT that may also have an aggressi-
ve behavior (22). 
Wnt5a function is conflicting since it may activate or in-
activate the canonical Wnt/β catenin signaling pathway 
(7,16,17). Likewise, it is interesting to notice this Wnt5a 
antagonism in the literature, as its expression can vary 
from 0 to 100% in different series of AME (4,16,23). 
This great variation seems to be dependent on differen-
tiation of tumor cells or on cell surface receptors avai-
lable, or by the use of different clones of the antibody 
(4,16,19). In the present series of AME, Wnt5a was 
identified in about half of the cases, which may be justi-
fied by the possibility of this glycoprotein activate or in-
activate the canonical Wnt/β catenin signaling pathway 
and by the fact that AME also present a great variation of 
radiographic presentation including from minor to major 
lesions (12,16).
Wnt1 and Wnt5a immunoexpression on CCOT revealed 
to be heterogeneous and consistent positive on the lining 
epithelium of this OT. Considering the benign and non-
aggressive clinical behavior of CCOT, we could specu-
late that Wnt5a acts as an inhibitor of canonical Wnt/β 
catenin signaling pathway in balance with the Wnt1 ac-
tivator. To support this statement, it is noteworthy that 
evidences of the suppressor potential of Wnt5a had been 
already described in the literature in AME, a benign lo-
cally aggressive OT (16). Also, Wnt1 and Wnt5a posi-
tivity was identified in the ghost cells of CCOT in the 
present study, a finding not previously reported. Once 
the canonical Wnt/β catenin signaling pathway is pro-
bably activate, the expected β catenin cytoplasm and/or 
nucleus expression in the ghost cells of the present series 
of CCOT was not identified. β catenin had neither been 
identified in the ghost cells in CCOT, pilomatrixoma and 
craniopharyngioma in a study concerning the main en-
tities microscopically characterized by the presence of 
ghost cells (24), but it was previously identified on ghost 
cells cytoplasm from odontomas (25). Thus, in brief, 
it seems that only Wnt plays a role in both CCOT and 
ghost cells histogenesis (26).
β-catenin accumulation in the cytoplasm will allow 
β-catenin translocation into the nucleus, and conse-
quently, will induce the expression of different genes as-
sociated with cell proliferation, as already demonstrated 
in odontogenesis and in some benign and malignant neo-
plasms (6-8,27). It is interesting to notice that even when 
cytoplasmic and nuclear β-catenin accumulation have 
been identified in AME (3,8,28), a mutation in the gene 
encoding  this protein was not identified (2,8,29,30). Un-
likely, this mutation had already been identified in CCOT 
(2,6), which also were immunohistochemically positive 
for cytoplasmic and nuclear β-catenin in the ameloblas-
toma-like epithelium of most of the cases (5,6,25), as 
seen in the present study. 
Additionally, we were not able to observe a single AME 
presenting nuclear β-catenin immunoexpression in the 
present series, which may be a result of the limited num-
ber of cases. Another interpretation is that the common 
presence of Wnt5a, a glycoprotein capable of inhibiting 
the Wnt/β catenin signaling pathway, could promote this 
low β-catenin nucleus accumulation. Nevertheless, the 
unexpected β-catenin cytoplasm accumulation is an im-
portant pre-requisite for β-catenin nucleus accumulation 
and it was observed in nearly 80% of the cases of AME.
The present study contributes to reinforce the possible 
relationship of the canonical Wnt/β-catenin signaling 
pathway in the process of tumorigenesis in both AME 
and CCOT, especially because the positive relationship 
between Wnt1 immunoexpression and cytoplasmic and/
or nuclear β-catenin immunoexpression in the epithe-
lium of both AME and CCOT. Wnt5a immunoexpres-
sion identified in half of the cases of AME may express 
both its activating and inactivating role; and Wnt5a im-
munoexpression identified in all cases of CCOT may 
express a balance between the activator Wnt1 and the 
inactivator Wnt5a in CCOT. It also seems that Wnt1 and 
Wnt5a take part of ghost cells development in CCOT. 
Further studies concerning these and other components 
of this signaling pathway, including the use of techni-
ques that demonstrate the activity of these molecules, 
may contribute to elucidate the pathogenesis of both 
AME and CCOT.
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